Work published in Science last week gave new insights into how the mammalian target of rapamycin (mTOR) complex 1 (mTORC1) figures out whether it’s feast or famine, nutrient-wise. Read More
The next few months are going to be busy ones for biotech executives as they rack up frequent flyer miles in order to attend a number of scheduled investor-focused conferences, which culminate in the always popular J.P. Morgan Healthcare Conference in San Francisco in January. A presentation at these upcoming events ranks highly on the list of tasks biotech execs have to do in the never-ending quest to attract investment capital and potential partners for their companies. For most, the endeavors have been rewarding of late. Read More
